CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
Portfolio Pulse from Benzinga Newsdesk
CervoMed Inc. (NASDAQ:CRVO) announced positive results from the AscenD-LB Phase 2a trial of neflamapimod for dementia with Lewy bodies (DLB), showing significant reduction in plasma GFAP levels compared to placebo. The reduction in GFAP correlated with improved clinical outcomes. Additionally, data from UCL demonstrated neflamapimod's potential in improving axonal transport in a tauopathy mouse model, supporting its use in frontotemporal dementia treatment. These findings will be presented at the AD/PD™ 2024 conference.
March 05, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CervoMed Inc. announced positive trial results for neflamapimod in treating DLB, showing significant reduction in GFAP levels and improved clinical outcomes. UCL data also supports its potential in treating FTD.
The positive results from the AscenD-LB Phase 2a trial and the supportive data from UCL research highlight neflamapimod's potential efficacy in treating DLB and FTD. This could lead to increased investor confidence in CervoMed's pipeline and potentially boost the stock price in the short term due to the positive outlook on the drug's development and its potential market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100